Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McLaughlin

Showing results (571-580 of 726) with videos related to

Pageof 73
Sort By:
Clinical Lymphoma|November 15, 2001
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?C Visco, L J Medeiros, O M Mesina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaA Younes, H A Preti, F B Hagemeister, et al.
International Journal of Molecular Sciences|September 9, 2022
Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel AnalgesicsJay P McLaughlin, Ramanjaneyulu Rayala, Ashley J Bunnell, et al.
Breast Cancer Research and Treatment|August 8, 2019
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancerJichao He, Ronan P McLaughlin, Vera van der Noord, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1991
Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's diseaseF B Hagemeister, L M Fuller, W S Velasquez, et al.
Molecules (Basel, Switzerland)|June 10, 2022
Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic PainLisa L Wilson, Amy R Alleyne, Shainnel O Eans, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989
High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experienceJ A Spinolo, S Jagannath, K A Dicke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphomaN L Berinstein, A J Grillo-López, C A White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Trimetrexate in relapsed T-cell lymphoma with skin involvementA H Sarris, A Phan, M Duvic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapyM S Czuczman, A J Grillo-López, P McLaughlin, et al.
Pageof 73

Showing results (571-580 of 726) with videos related to

Sort By:
Pageof 73
Clinical Lymphoma|November 15, 2001
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?C Visco, L J Medeiros, O M Mesina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaA Younes, H A Preti, F B Hagemeister, et al.
International Journal of Molecular Sciences|September 9, 2022
Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel AnalgesicsJay P McLaughlin, Ramanjaneyulu Rayala, Ashley J Bunnell, et al.
Breast Cancer Research and Treatment|August 8, 2019
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancerJichao He, Ronan P McLaughlin, Vera van der Noord, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1991
Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's diseaseF B Hagemeister, L M Fuller, W S Velasquez, et al.
Molecules (Basel, Switzerland)|June 10, 2022
Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic PainLisa L Wilson, Amy R Alleyne, Shainnel O Eans, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989
High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experienceJ A Spinolo, S Jagannath, K A Dicke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphomaN L Berinstein, A J Grillo-López, C A White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Trimetrexate in relapsed T-cell lymphoma with skin involvementA H Sarris, A Phan, M Duvic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapyM S Czuczman, A J Grillo-López, P McLaughlin, et al.
Pageof 73